Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Observational Retrospective Case Review of Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Males and Females With Anderson-Fabry Disease

NCT01268241 is registered in ClinicalTrials.gov with CENTOGENE GmbH Rostock as lead sponsor.

NCT NCT01268241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01268241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Observational Retrospective Case Review of Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Males and Females With Anderson-Fabry Disease
Lead sponsor
CENTOGENE GmbH Rostock
Phase
Observational
Overall status
Completed
Start date
December 31, 2010
Completion date
April 30, 2016
Enrollment
200 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

anderson-fabry disease, fabry disease, fabry´s disease